News Releases

 

BioSante Pharmaceuticals to Present at Merriman Curhan Ford’s Investor Summit

LINCOLNSHIRE, Illinois (November 10, 2009) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Phillip B. Donenberg, its CFO, will present an overview of the company and its recently completed acquisition of Cell Genesys, as well as give a LibiGel® (testosterone gel) update at Merriman Curhan Ford’s 6th Annual Investor Summit today, Tuesday November 10, 2009 at the Hotel Sofitel in New York City. Mr. Donenberg will present at 12:40 pm local time.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S.

Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. Under BioSante’s license agreement with Antares Pharma, BioSante is required to pay Antares a portion of the royalties, license and milestone payments received for products covered by that agreement. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at: biosantepharma.cdmail.biz.

###

For more information please contact:

For Media:
Harris D. McKinney, Inc.
Alan Zachary
(312) 506-5220
azachary@harrisdmckinney.com

For information about participating in the LibiGel clinical studies call or visit the following:
877-BLOOM81;